Alpha Fetoprotein Secretion
Alpha Fetoprotein Secretion - Related Videos
01:30
Detection of Phosphorylated Alpha-Synuclein Using Western Blotting
0 Views •
2025
Add a loading buffer containing a detergent, a reducing agent, and a tracking dye.
03:25
Immunostaining of Neurons Treated with Alpha-Synuclein Aggregates
0 Views •
2025
This video demonstrates the immunostaining of neurons treated with alpha-synuclein (αS) aggregates. The neurons are first treated with αS aggregates. They are then fixed, permeabilized, and treated with a blocking solution. Primary antibodies are added, followed by a fluorescently labeled secondary antibodies and a nuclear stain. The sample is then mounted and observed under a microscope.
03:11
Quantification of Bioactive Type-I Interferons using a Secreted Embryonic Alkaline Phosphatase Reporter Assay
0 Views •
2025
This video demonstrates secreted embryonic alkaline phosphatase assay using HEK-Blue interferon-α/β reporter cells to quantify the type-I interferons (IFNs) released following stimulation of plasmacytoid dendritic cells by HIV-1 Infected CD4+ T cells.
11:53
Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System
0 Views •
Cited by 37 •
2010
Parkinson's disease has been related to the exposure to pesticides. Here we show a method to deliver pesticides using a gastric tube at the desired concentration and a method to analyze their effect in alpha-synuclein accumulation in the enteric nervous system.
02:12
Induction of Neuroinflammation in Mice via Injection of Alpha-Synuclein Fibrils
0 Views •
2025
This video demonstrates the injection of alpha-synuclein fibrils into a mouse to induce neuroinflammation. The fibrils are injected intraperitoneally into a transgenic mouse expressing mutated alpha-synuclein proteins. Upon reaching the central nervous system, the fibrils enter neurons and induce aggregation of the mutated proteins. The aggregates spread to neighboring neurons, microglia, and astrocytes. Recognition of the aggregates triggers microglia to induce neuroinflammation, damaging the...
FAQs
AFP secretion depends on coordinated activity across specialized fetal cell types and the secretory pathway. Hepatocytes and yolk sac cells synthesize the protein, after which the endoplasmic reticulum and Golgi apparatus process it before release. This cellular organization connects the site of production with the appearance of AFP in fetal circulation and supports its use in developmental studies.
The postnatal decline reflects a developmental change in the predominant serum protein. AFP production is high during embryonic growth, whereas albumin becomes predominant after birth. Tracking this shift helps distinguish expected developmental patterns from situations in which AFP remains elevated, making the transition relevant to both developmental biology and interpretation of circulating protein measurements.
Regulated AFP production provides a biological link between tissue state and measurable serum protein levels. Normal production follows a developmental pattern, while altered levels may accompany pregnancy, liver injury, hepatocellular carcinoma, or certain germ cell tumors. Consequently, AFP can help characterize development or disease, but its concentration cannot identify a single condition without additional clinical context.
Circulating AFP measurements support prenatal screening by providing information related to fetal developmental status. Their value comes from comparing observed levels with the expected developmental context rather than interpreting an isolated result. Because pregnancy itself can affect AFP levels, screening findings require appropriate clinical interpretation and should not be treated as a definitive diagnosis on their own.
AFP secretion becomes relevant in evaluating hepatocellular carcinoma and certain germ cell tumors because these diseases can be associated with elevated circulating AFP. The measurement offers a biomarker-based perspective on disease assessment, but elevation is not unique to cancer. Pregnancy, liver injury, and other conditions can also contribute, so results must be considered alongside the broader clinical picture.
An elevated AFP result does not point exclusively to malignancy or abnormal development. Pregnancy, liver injury, and other conditions may also increase circulating levels, creating possible overlap between physiological, injury-related, and disease-associated patterns. Interpretation therefore depends on clinical context, and the measurement is most useful as part of a broader assessment rather than as an isolated conclusion.
Studying AFP secretion connects a normal embryonic protein-production pattern with clinical biomarker research. Developmental biology explains why AFP is prominent before birth and declines afterward, while diagnostic research examines how circulating levels relate to prenatal screening, liver disease, and tumors. This connection allows the same biological process to inform both fundamental development studies and disease evaluation.